Comparative analysis prediction of prostate and testicular cancer mortality using machine learning: accuracy study

利用机器学习对前列腺癌和睾丸癌死亡率进行比较分析预测:准确性研究

阅读:3

Abstract

BACKGROUND: The mortality rates of prostate and testicular cancer are higher mortality in the northeast region. OBJECTIVE: We aimed to compare the efficacy of machine learning libraries in predicting testicular and prostate cancer mortality. DESIGN AND SETTING: A comparative analysis of the pyMannKendall and Prophet machine-learning algorithms was conducted to develop predictive models using data from DATASUS (TabNet) to Caicó (Brazil) and Rio Grande do Norte (Brazil). METHODS: Data on prostate and testicular cancer mortality in men from 2000 to 2019 were collected. The prediction accuracy of the Prophet algorithm was evaluated using the mean squared error (MSE), the root mean squared error and analyzed using the pyMannKendall, and Prophet libraries. RESULTS: The research data were made publicly available on GitHub. The machine test confirmed the accuracy of the predictions, with the root MSE (RMSE) values closely matching the observed data for Caicó (RMSE = 2.46) and Rio Grande do Norte (RMSE = 22.85). The Prophet algorithm predicted an increase in prostate cancer mortality by 2030 in Caicó and Rio Grande do Norte. This prediction was corroborated by the pyMannKendall analysis, which indicated a 99% probability of a rising mortality trend in Caicó (P < 0.01; tau = 0.586; intercept = 2.59) and Rio Grande do Norte (P = 2.06; tau = 0.84, and intercept = 119.63). For testicular cancer, no significant mortality trend was identified by Prophet or pyMann-Kendall. CONCLUSIONS: Libraries are reliable tools for predicting mortality, providing support for strategic health planning, and implementing preventive measures to ensure men's health. Addressing the gender gap in DATASUS is essential.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。